Britain has approved Novavax's COVID-19 vaccine for use in those 18 years of age and older, the country's medicines regulator said on Thursday, bringing a fifth coronavirus shot to its roster amidst the rapid spread of the Omicron variant.
"Nuvaxovid will be the first protein-based vaccine option authorized by MHRA as the United Kingdom tackles this next phase of the pandemic," Novavax Chief Executive Stanley Erck said in a statement.
Novavax's vaccine last June was found to be more than 90% effective in a U.S. trial against a variety of variants, including Delta, while early data from December also suggests it would work against Omicron.for the supply of 60 million doses of the shot, while also agreeing to collaborate on conducting late-stage trials for the vaccine in the country.
Following the approval by the MHRA, the Joint Committee on Immunisation and Vaccination will release guidelines for the use of the vaccine in Britain's COVID-19 vaccination programme.Reporting by Pushkala Aripaka in Bengaluru; Additional reporting by Manas Mishra; Editing by Aditya Soni and David EvansSubscribe to our daily curated newsletter to receive the latest exclusive Reuters coverage delivered to your inbox.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
US Army to 'immediately' start discharging those who refuse COVID-19 vaccineThe US Army said it will 'immediately' start discharging those who don't comply with COVID vaccine mandate as omicron variant cases continue to surge.
Les mer »
COVID-19 live updates: Santa Clara Co. approves extra vaccine dose for immunocompromisedTransplant recipients, cancer patients and people with immunodeficiencies can now receive a third dose of the Moderna or Pfizer vaccine in Santa Clara County.
Les mer »
The FDA Just Approved Another COVID-19 VaccineIt's the second vaccine to receive full FDA approval.
Les mer »
Regulators urge Pfizer to apply for COVID-19 vaccines for kids under 5Early Pfizer data has shown the vaccine — which is administered to younger kids at one-tenth the strength of the adult shot — is safe and produces an immune response.
Les mer »